Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
Cross-reactivity00:42

Cross-reactivity

33.4K
Overview
33.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local immunotherapy for the treatment of cancer: scientific advances and clinical potential.

Journal for immunotherapy of cancer·2026
Same author

Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors.

Computational and structural biotechnology journal·2026
Same author

Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses.

Cancer immunology research·2026
Same author

Locally Advanced Conjunctival Squamous Cell Carcinoma not Responsive to Immune Checkpoint Inhibitor Therapy: 3 Cases and a Literature Review.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Letter to the EditorTumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy.

Neuro-oncology·2025
Same author

Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Mar 3, 2026

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.0K

Rational Combination Immunotherapy: Understand the Biology.

Howard L Kaufman1

  • 1Departments of Surgery and Medicine, Rutgers University, New Brunswick, New Jersey. howard.kaufman@rutgers.edu.

Cancer Immunology Research
|May 4, 2017
PubMed
Summary

Inhibiting CD47 in lung cancer models reduced tumors but increased autophagy. Combining CD47 and autophagy inhibition significantly improved therapeutic response, revealing new avenues for cancer immunotherapy.

Area of Science:

  • Cancer Immunology
  • Immunotherapy
  • Tumor Biology

Background:

  • Selecting effective combination therapies is crucial for enhancing cancer immunotherapy outcomes.
  • CD47 inhibition has shown potential in reducing tumors, but its impact on other cellular processes needs investigation.
  • The Akt/mTOR pathway plays a role in cellular regulation and can be influenced by therapeutic interventions.

Purpose of the Study:

  • To investigate the effects of CD47 inhibition on tumor growth in a lung carcinoma model.
  • To explore the relationship between CD47 inhibition, the Akt/mTOR pathway, and autophagy.
  • To determine if targeting autophagy can enhance the therapeutic efficacy of CD47 inhibition.

Main Methods:

  • Utilized a lung carcinoma mouse model.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Related Experiment Videos

Last Updated: Mar 3, 2026

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

  • Administered CD47 inhibitors to assess tumor reduction.
  • Analyzed the Akt/mTOR pathway and autophagy induction in response to treatment.
  • Combined CD47 inhibition with autophagy targeting agents.

    • Main Results:

    • CD47 inhibition led to tumor reduction in the lung carcinoma model.
    • CD47 inhibition inadvertently induced autophagy via Akt/mTOR pathway inhibition.
    • Co-targeting autophagy alongside CD47 significantly improved the therapeutic response.

    Conclusions:

    • Understanding the underlying biology of antitumor immunity is essential for optimizing cancer treatments.
    • The interplay between CD47, autophagy, and the Akt/mTOR pathway presents a potential therapeutic target.
    • Combination strategies involving CD47 and autophagy inhibition warrant further investigation for improved cancer immunotherapy.